Obesity is a growing health concern worldwide, with at least 2.8 million people dying each year as a result of the disease. Additionally, the number of individuals living with obesity continues to increase annually across age, gender and geographic location. A complex condition, obesity has implications in inflammatory, metabolic and cardiovascular health — which, together, mean that advancing the treatment of obesity also means accounting for its relationships with other physiological systems and health conditions.

Recently, treatment for obesity has made great strides, with newly approved drugs gaining a great deal of attention from patients, clinicians and providers alike. As sponsors and researchers look to progress the field of obesity treatment, there are a number of unique considerations to account for in their approach to development and clinical trials.

Read the whitepaper to learn:

• The foundational physiology and drivers of obesity
• How obesity impacts inflammatory, metabolic and cardiovascular health
• Current approaches to treating obesity
• Considerations for future obesity drug development, including long-term health solutions and multidisciplinary and combination therapies
• Unique challenges and approaches in participant recruitment and retention for obesity-related clinical trials
• Considerations for clinical trial design focused on obesity treatments
• Why and how to plan for long-term follow-up for obesity treatments.